Insilico bets AI can design a working drug; rentosertib hits Phase IIa, then HKEX

Insilico Medicine builds the Pharma.AI platform (PandaOmics for target discovery, Chemistry42 for molecule design) and runs its own clinical pipeline, led by the TNIK inhibitor rentosertib (ISM001-055) for idiopathic pulmonary fibrosis.

Generative AI can do end-to-end drug discovery: find a novel target and design a molecule that works in humans, so one Phase II readout validates or sinks the platform.

Reuters reported a $255M financing in June 2021; $110M Series E led by Value Partners (Mar 2025) at a unicorn valuation; HKEX IPO raised HKD 2.277 billion (Dec 2025).

Founded in the US in 2014 by Alex Zhavoronkov, Insilico Medicine spent its early years publishing AI-for-biology research — a 2019 Nature Biotechnology paper showed its GENTRL model generating a DDR1 inhibitor in 21 days. It then bet the company on end-to-end generative drug discovery: target discovery, molecule design and clinical development all driven by its Pharma.AI platform.

In 2019 PandaOmics flagged TNIK as a novel IPF target; Chemistry42 designed ISM001-055, and the preclinical candidate was nominated in February 2021, 18 months after target identification. Phase 0 and two Phase I trials (New Zealand and China) showed safety, and in February 2023 the drug received FDA Orphan Drug Designation. In March 2024 Nature Biotechnology published the full journey from target to Phase II. The China Phase IIa (NCT05938920) enrolled 71 patients across 21 sites; in September 2024 Insilico reported positive preliminary results, and in November 2024 the topline showed a dose-dependent FVC improvement — +98.4 mL at 60 mg once daily versus a decline in the placebo arm — with a favorable safety profile, while a parallel US Phase IIa (NCT05975983) also read out positive.

In March 2025 Insilico closed a $110M Series E led by Value Partners at a unicorn valuation; on December 30, 2025 it listed on the HKEX main board (03696.HK), raising HKD 2.277 billion in the year's largest Hong Kong biotech IPO, with the public tranche oversubscribed about 1,427 times and cornerstones including Lilly, Tencent and Temasek. On July 7, 2026 the renamed rentosertib entered a Phase III trial (320 patients across 47 Chinese sites) — the first AI-discovered-target, AI-designed-molecule drug to reach late-stage testing.

End-to-end scope was the differentiator: most AI-biotech companies sell software or optimize one step; Insilico took both target and molecule through the clinic itself.

Publishing early and repeatedly (2019 GENTRL, 2024 Nature Biotechnology) built credibility that carried fundraising when clinical data did not yet exist.

The dose-dependent FVC result converted narrative into data: the placebo arm declined while the 60 mg arm improved by 98.4 mL over 12 weeks.

Monetizing the platform early — out-licensing deals worth up to $2.1B with Fosun, Exelixis and Menarini, plus software deals with 13 of the top 20 pharma — funded the long clinical haul.

A platform bet needs a human proof point: Insilico's unicorn story became bankable only when one Phase IIa FVC number validated an AI-discovered target plus an AI-designed molecule.

As of 2026-09-02, Insilico Medicine (03696.HK) is public — the first AI-driven biotech under HKEX Chapter 8.05 — after raising HKD 2.277 billion. Rentosertib entered a 320-patient, 52-week Phase III in China on July 7, 2026, the most advanced AI-discovered and AI-designed drug, and its readout is treated as the field's decisive test. The company runs 30-plus pipeline programs (10 IND clearances), software collaborations with 13 of the top 20 pharma companies, out-licensing deals worth up to $2.1B, and a 249-person R&D team.